The incidences of cancer are scaling new heights in the second most populous country of the world. Ignorance about cancer and its symptoms coupled with a delay in medical assistance for proper diagnosis has accentuated the prevalence of this illness which is anticipated to grow by 30% in the next 5 years globally. In India, every year there are around 1,157,294 million new cases of cancer and around 784,821 deaths in the country. It is stated that the risk of developing cancer after the age of 75 years in male is 9.81% and in the female is 9.42% in India, while the risk in the age group of 40 to 60 has shown massive growth over the past couple of years.
According to MarkNtel Advisors’ research report “India Cancer Treatment Market Analysis, 2020”, the India Cancer Treatment Market is anticipated to grow at a substantial CAGR during 2020-25. Unclear patent laws, preventive pricing, and reimbursement policies, less developed infrastructure are curbing the growth in the market.
Breast Cancer Segment Slated to Gain the Maximum Share
Breast cancer is one of the most common cancers to affect women in India. Lack of awareness aids in the snowballing numbers every year. Oncologists suggested cancer literacy amongst women especially those between 40 and 60 years for them to undergo a regular screening schedule which would help diagnose cancers in the embryonic stages and support doctors to treat them. In India, there were around 0.2 million breast cancer cases in 2019, according to WHO. The three most common cancers that affect men in India are Prostate, Lung, and Colorectal. Oral cancer is a major health problem in India as in most cases it gets detected only in the later stages with high expenses and no cure. Owing to the excessive usage of tobacco and its addiction to tobacco substitutes especially in the lower socio-economic classes of the country, resulting in the induced number of tobacco cancer cases. The total number of tobacco cancer deaths in 2019 in the country were estimated to be around 0.35 million including men and women, according to the National Institute of Cancer Prevention and Research. The urban women are affected more by cancers of the uterus, ovaries, and lungs in the country. The Indian Council of Medical Research (ICMR) data has states the number of cancer cases to increase at an estimated number of 1.45 million new cases every year.
Targeted Therapy Remained Dominant
The targeted radiation therapy segment grabbed the major market share in 2019. However, sturdy growth has been witnessed by the immunotherapy segment which is expected to escalate during 2020-25. Immunotherapy drugs are extensively accepted as an ideal treatment option as these drugs are harmless to the other living cells of the body which makes them less toxic as compared to other modes of cancer therapies. Moreover, constant efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types are positively driving the India cancer treatment market in 2019 as revealed by the MarkNtel Advisors’ research report “India Cancer Treatment Market Analysis, 2020”.
According to MarkNtel Advisors’, the key players with a considerable market share in the India Cancer Treatment market include Amgen, AstraZeneca Plc, Merck and Co., Novartis AG, Pfizer Inc., Bayer AG, Astellas Pharma Inc., Celgene Corporation, Bristol-Myers Squibb, F. Hoffmann-La-Roche Ltd., Johnson and Johnson, etc. In 2019, a drug firm Emcure Pharmaceuticals launched generic metastatic breast cancer treatment drug under the brand name 'Eribilin' in India.
“India Cancer Treatment Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for Cancer Treatment providers. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.
1. By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other Treatment Types),
2. By Type (Blood Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Non-Hodgkin’s Lymphoma, Respiratory/ Lung Cancer, Stomach Cancer, Other Cancers),
3. By End-Users (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers),
4. By Region (North, South, East, West),
5. By Company (Amgen, AstraZeneca Plc, Merck and Co., Novartis AG, Pfizer Inc., Bayer AG, Astellas Pharma Inc., Celgene Corporation, Bristol-Myers Squibb, F. Hoffmann-La-Roche Ltd., Johnson and Johnson, etc.)
Key questions answered in the study:
1. What are the current and future market trends of the Cancer Treatment industry?
2. How the industry has been evolving in terms of end-user demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Cancer Treatment industry?